Sun Pharma acquires Disperzyme and Phlogam brands to its anti-inflammatory portfolio

Sun Pharma acquires Disperzyme and Phlogam brands to its anti-inflammatory portfolio

Disperzyme and Phlogam are fixed dose combination of proteolytic enzymes and bioflavonoid viz., Tryspin, Bromelain and Rutoside.

FPJ Web DeskUpdated: Monday, January 30, 2023, 12:34 PM IST
article-image
Sun Pharma acquires Disperzyme and Phlogam brands to its anti-inflammatory portfolio | Image: Sun Pharma (Representative)

Sun Pharmaceutical Industries Limited today announced that it has acquired three brands viz. Disperzyme, Disperzyme-CD and Phlogam from Aksigen Hospital Care, via an exchange filing.

Aksigen is a Mumbai-based research-driven healthcare entity with more than two decades of experience in the healthcare field.

All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures.

Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (TBR) to complete a clinical study in India and get DCGI approval.

The brands were registered and launched in India by Aksigen in 2013.

Kirti Ganorkar, CEO-India business, Sun Pharma, said, “The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds-up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation.”

The overall market of proteolytic enzyme for healing, pain and edema in India is around Rs.500 crores (as per IQVIA data MAT Nov 2022).

RECENT STORIES

Market Meltdown: Sensex & Nifty Continue Downward Spiral Ahead Of Lok Sabha Election Results,...

Market Meltdown: Sensex & Nifty Continue Downward Spiral Ahead Of Lok Sabha Election Results,...

Alembic Pharma Gets USFDA Nod To Market Heart Failure Drug

Alembic Pharma Gets USFDA Nod To Market Heart Failure Drug

Capital Needs To Remain High For Corporates: Moody's

Capital Needs To Remain High For Corporates: Moody's

Shriram Properties Profit Up 32% In January-March To ₹20 Crore

Shriram Properties Profit Up 32% In January-March To ₹20 Crore

From The Streets Of Barcelona To Electrifying You: Cupra Tavascan

From The Streets Of Barcelona To Electrifying You: Cupra Tavascan